4.5 Review

Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy

Journal

MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume 17, Issue 18, Pages 1746-1757

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557516666160219122524

Keywords

Bioactive(s) delivery; cancer; chemotherapeutics; nanomedicine; theranostics; WHO

Funding

  1. Indian Council of Medical Research (ICMR) India
  2. Council of Scientific & Industrial Research (CSIR), New Delhi
  3. Department of Science and Technology (DST), India
  4. ICMR
  5. CSIR
  6. DST-INSPIRE

Ask authors/readers for more resources

In the recent years, theranostic nanomedicine based strategies have gained much attention in the field of oncology particularly, in the development of new generation cancer diagnostic and therapeutic tools. Today, various approaches have been developed for bioactive(s) targeting to predefined pathological sites, as well as for quantification of physiological processes and visualization. Significant attempts have been made to combine therapeutic and diagnostic properties in to a single effective nanomedicine formulation. This concept, coined as theranostics is smart nanosystem(s), able to diagnose, bioactive(s) delivery and monitoring of therapeutic response. By combining therapeutic functionalities with molecular imaging, theranostic based strategies may be beneficial in the selection of therapy, planning of treatment, monitoring of objective response and planning of follow-up therapy based on the specific molecular characteristics of a disease. In this manuscript, we reviewed the recent development of theranostic approaches, various nanosystems as theranostic agents and applications of theranostic in cancer therapeutics and diagnostics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available